Telo Genomics Corp. (TDSGF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.88 Million CAD | 33.66% |
| 2022 | 2.11 Million CAD | 67.87% |
| 2021 | 1.25 Million CAD | -4.09% |
| 2020 | 1.31 Million CAD | 24.43% |
| 2019 | 1.05 Million CAD | -77.14% |
| 2018 | 4.6 Million CAD | -50.46% |
| 2017 | 9.3 Million CAD | 12555.13% |
| 2016 | 73.49 Thousand CAD | -34.29% |
| 2015 | 111.84 Thousand CAD | 258.67% |
| 2014 | 31.18 Thousand CAD | -68.27% |
| 2013 | 98.29 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 605.17 Thousand CAD | -25.18% |
| 2024 Q1 | 672.54 Thousand CAD | -21.33% |
| 2024 Q2 | 823.42 Thousand CAD | 22.43% |
| 2023 Q1 | 615.8 Thousand CAD | -5.73% |
| 2023 FY | 2.82 Million CAD | 33.66% |
| 2023 Q2 | 639.21 Thousand CAD | 3.8% |
| 2023 Q3 | 710.88 Thousand CAD | 11.21% |
| 2023 Q4 | 854.87 Thousand CAD | 20.25% |
| 2022 Q2 | 463.29 Thousand CAD | -3.27% |
| 2022 Q1 | 478.94 Thousand CAD | 0.74% |
| 2022 FY | 2.11 Million CAD | 67.87% |
| 2022 Q4 | 653.23 Thousand CAD | 26.85% |
| 2022 Q3 | 514.98 Thousand CAD | 11.16% |
| 2021 FY | 1.25 Million CAD | -4.09% |
| 2021 Q3 | 309.6 Thousand CAD | 13.07% |
| 2021 Q2 | 273.81 Thousand CAD | 38.24% |
| 2021 Q1 | 198.07 Thousand CAD | -50.83% |
| 2021 Q4 | 475.4 Thousand CAD | 53.55% |
| 2020 FY | 1.31 Million CAD | 24.43% |
| 2020 Q1 | 138.64 Thousand CAD | -24.57% |
| 2020 Q2 | 561.04 Thousand CAD | 304.67% |
| 2020 Q3 | 321.42 Thousand CAD | -42.71% |
| 2020 Q4 | 402.86 Thousand CAD | 25.34% |
| 2019 Q2 | 176.02 Thousand CAD | -69.61% |
| 2019 FY | 1.05 Million CAD | -77.14% |
| 2019 Q4 | 183.79 Thousand CAD | 60.59% |
| 2019 Q3 | 114.44 Thousand CAD | -34.98% |
| 2019 Q1 | 579.25 Thousand CAD | -46.35% |
| 2018 Q2 | 1.55 Million CAD | 45.41% |
| 2018 FY | 4.6 Million CAD | -50.46% |
| 2018 Q4 | 1.07 Million CAD | 19.12% |
| 2018 Q3 | 906.43 Thousand CAD | -41.65% |
| 2018 Q1 | 1.06 Million CAD | -50.69% |
| 2017 FY | 9.3 Million CAD | 12555.13% |
| 2017 Q3 | 2.16 Million CAD | 34.69% |
| 2017 Q1 | 3.36 Million CAD | 17508.11% |
| 2017 Q2 | 1.6 Million CAD | -52.23% |
| 2017 Q4 | 2.16 Million CAD | 0.14% |
| 2016 Q3 | 45.84 Thousand CAD | -24.74% |
| 2016 Q2 | 60.91 Thousand CAD | 2845.25% |
| 2016 Q1 | -2219.00 CAD | -126.58% |
| 2016 FY | 73.49 Thousand CAD | -34.29% |
| 2016 Q4 | 19.09 Thousand CAD | -58.35% |
| 2015 FY | 111.84 Thousand CAD | 258.67% |
| 2015 Q4 | 8348.00 CAD | 29.53% |
| 2015 Q3 | 6445.00 CAD | -63.81% |
| 2015 Q2 | 17.8 Thousand CAD | 45.55% |
| 2015 Q1 | 12.23 Thousand CAD | -53.36% |
| 2014 FY | 31.18 Thousand CAD | -68.27% |
| 2014 Q1 | 4498.00 CAD | -64.2% |
| 2014 Q2 | 6580.00 CAD | 46.29% |
| 2014 Q3 | 55.57 Thousand CAD | 744.54% |
| 2014 Q4 | 26.23 Thousand CAD | -52.79% |
| 2013 Q2 | -10.74 Thousand CAD | -243.75% |
| 2013 Q4 | 12.56 Thousand CAD | 66.59% |
| 2013 FY | 98.29 Thousand CAD | 0.0% |
| 2013 Q3 | 7542.00 CAD | 170.18% |
| 2013 Q1 | 7476.00 CAD | -41.98% |
| 2012 Q4 | 12.88 Thousand CAD | -85.47% |
| 2012 Q3 | 88.67 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -175.099% |
| Arrayit Corporation | 6.19 Million USD | 53.437% |
| Atlantic International Corp. | 5.57 Million USD | 48.267% |
| Biocept, Inc. | 29.4 Million USD | 90.185% |
| Bioqual, Inc. | 7.44 Million USD | 61.258% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -273.738% |
| DermTech, Inc. | 104.01 Million USD | 97.226% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 98.267% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 87.244% |
| iMD Companies, Inc. | 151.8 Thousand USD | -1800.935% |
| IDenta Corp. | 662.97 Thousand USD | -335.279% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 85.737% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -7322.111% |
| InVitro International | 661.32 Thousand USD | -336.366% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 59.344% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -4865.912% |
| Medical Imaging Corp. | 1.91 Million USD | -50.918% |
| NovelStem International Corp. | 3.53 Million USD | 18.43% |
| Optigenex Inc. | 1.28 Million USD | -124.075% |
| PharmChem, Inc. | 2.93 Million USD | 1.55% |
| Proteome Sciences plc | 3.26 Million USD | 11.696% |
| Response Genetics, Inc | 25.31 Million USD | 88.602% |
| Rennova Health, Inc. | 7.67 Million USD | 62.414% |
| RushNet, Inc. | 1.78 Million USD | -61.279% |
| ScreenPro Security Inc. | 3.23 Million USD | 10.902% |
| Stella Diagnostics Inc. | 11.42 Million USD | 74.746% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 60.7% |
| Todos Medical Ltd. | 14.05 Million USD | 79.472% |